Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerGiorgio V. Scagliotti, David R. Gandara, Purvish Parikh et al.|Journal of Clinical Oncology|2008Cited by 3.2k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Silvia Novello, R. Kaiser et al.|The Lancet Oncology|2014Cited by 948
Detection and characterization of lung cancer using cell-free DNA fragmentomesDimitrios Mathios, Victor E. Velculescu, Jakob Sidenius Johansen et al.|Nature Communications|2021Cited by 458
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Sergey Orlov et al.|The Lancet Oncology|2020Cited by 413
Geographical variations in the use of cancer treatments are associated with survival of lung cancer patientsHenrik Møller, James Spicer, Victoria H. Coupland et al.|Thorax|2018Cited by 44